Neumora Therapeutics, Inc.
NMRA
$1.20
-$0.05-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -43.08M | -53.46M | -59.45M | -56.76M | -52.73M |
| Total Depreciation and Amortization | 7.00K | 8.00K | 9.00K | 23.00K | 19.00K |
| Total Amortization of Deferred Charges | 394.00K | 418.00K | 1.21M | -- | 303.00K |
| Total Other Non-Cash Items | 7.25M | 7.39M | 7.07M | 5.62M | 7.61M |
| Change in Net Operating Assets | -4.09M | -765.00K | 3.21M | 4.48M | -7.60M |
| Cash from Operations | -39.53M | -46.40M | -47.96M | -46.63M | -52.40M |
| Capital Expenditure | -- | -- | 16.00K | -16.00K | -- |
| Sale of Property, Plant, and Equipment | 0.00 | 71.00K | 47.00K | 87.00K | 84.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 42.58M | 51.25M | 30.31M |
| Cash from Investing | 0.00 | 71.00K | 42.65M | 51.32M | 30.40M |
| Total Debt Issued | -- | -- | 38.90M | -136.00K | 18.40M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.74M | 10.88M | 19.87M | 0.00 | 59.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -445.00K | -- | -- | -- | -- |
| Cash from Financing | 9.29M | 10.88M | 58.77M | -136.00K | 18.46M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -30.24M | -35.46M | 53.46M | 4.55M | -3.55M |